Public Profile

Shionogi

Shionogi & Co., Ltd., commonly known as Shionogi, is a prominent pharmaceutical company headquartered in Osaka, Japan. Founded in 1878, Shionogi has established itself as a leader in the pharmaceutical industry, focusing on research and development in areas such as infectious diseases, pain management, and central nervous system disorders. With a strong presence in Japan and expanding operations in North America and Europe, Shionogi is renowned for its innovative core products, including antiviral treatments and analgesics. The company’s commitment to advancing healthcare solutions has led to significant milestones, including the development of groundbreaking therapies that address unmet medical needs. Shionogi's dedication to quality and innovation has positioned it as a key player in the global pharmaceutical market, earning recognition for its contributions to public health and patient care.

DitchCarbon Score

How does Shionogi's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

65

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Shionogi's score of 65 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.

99%

Let us know if this data was useful to you

Shionogi's reported carbon emissions

In 2023, Shionogi reported total carbon emissions of approximately 214,942,000 kg CO2e. This includes Scope 1 emissions of about 40,373,000 kg CO2e, Scope 2 emissions of approximately 31,650,000 kg CO2e (market-based), and significant Scope 3 emissions totalling around 142,919,000 kg CO2e. The company has set ambitious targets to reduce its emissions, aiming for a 46.2% reduction in both Scope 1 and Scope 2 emissions by 2030, based on 2019 levels. Additionally, Shionogi plans to cut Scope 3 emissions from purchased goods and services by 20% within the same timeframe. Shionogi is committed to achieving net-zero emissions across all scopes by 2050. The company has also established interim goals, including a near-zero target for Scope 1 emissions by 2025 and a 30% reduction in Scope 2 emissions from 2020 levels by 2030. These commitments align with industry standards for climate action and demonstrate Shionogi's dedication to sustainability and reducing its carbon footprint.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2017201820192020202120222023
Scope 1
43,456,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
46,681,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
196,761,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Shionogi's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Shionogi is in JP, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Shionogi is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Purdue Pharma L.P.

US
Pharmaceutical Preparation Manufacturing
Updated 12 days ago

Takeda

JP
Pharmaceutical Preparation Manufacturing
Updated about 21 hours ago

Shire plc

IE
Health and social work services (85)
Updated 4 months ago
DitchCarbon Score

Tris Pharma, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 23 days ago

DAIICHI SANKYO GROUP

JP
Pharmaceutical Preparation Manufacturing
Updated 6 days ago

Janssen

US
Pharmaceutical Preparation Manufacturing
Updated about 1 hour ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers